NCT04370236Phase 2, phase 3Terminated

INB03 for the Treatment of Pulmonary Complications From COVID-19

Study sponsor: Inmune Bio, Inc. · INMB

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-10-13Actual
Enrollment · participants79Actual
Source updated2026-05-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of Participants With Disease Progression From Randomization to 28 Days Post-randomization. After: Measure: Cochran-Mantel-Haenszel Analysis of Proportion of Patients With Disease Progression.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview